Reviva Pharma's schizophrenia drug succeeds in late-stage study

Reviva Pharmaceuticals' (RVPH.O) lead experimental drug to treat adults with schizophrenia helped reduce severity of disease symptoms in a late-stage study, sending the company's shares up nearly 8% on Monday.